CD8A and cancer: Our current study finds that miRNA-149-3p, identified by screening and assessing multiple miRNA profiles, potentially interacts with inhibitory T-cell receptors PD-1, Tim3, BTLA and PD-1-associated transcriptional factor Foxp1, and exerts potentially anti-cancer efficacy by reversing CD8+ T-cell exhaustion.